We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Health-related quality of life of daily-life-affected benign essential blepharospasm: Multi-center observational study.
- Authors
Hirunwiwatkul, Parima; Supawatjariyakul, Wajamon; Jariyakosol, Supharat; Apinyawasisuk, Supanut; Sriratanaban, Jiruth; Chongpison, Yuda; Jagota, Priya; Aui-aree, Nipat; Witthayaweerasak, Juthamat; Setthawatcharawanich, Suwanna; Kitthaweesin, Kitthisak; Chirapapaisan, Niphon; Chaimongkoltrakul, Piyawadee; Laowanapiban, Poramaet; Hansapinyo, Linda; Panpitpat, Suthida; Kurathong, Sireedhorn; Nimworaphan, Jirat; Thitiwichienlert, Suntaree; Vanikieti, Kavin
- Abstract
Purpose: To compare Thais' health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment. Design: Prospective-observational study. Participants: BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021. Methods: Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded. Results: 184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month. Conclusion: Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.
- Subjects
QUALITY of life; BOTULINUM A toxins; BOTULINUM toxin; BLEPHAROSPASM; EYE pain; SCIENTIFIC observation
- Publication
PLoS ONE, 2023, Vol 17, Issue 3, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0283111